Commitments and Contingencies (Details Narrative)																	12 Months Ended
	Nov. 21, 2018 USD ($)	Apr. 05, 2018 USD ($) $ / shares	Feb. 26, 2018 USD ($)	Dec. 09, 2017 USD ($) $ / shares shares	Jan. 18, 2017 USD ($)	Oct. 26, 2016 USD ($)	Jul. 21, 2016 USD ($)	Jan. 12, 2016 USD ($)	Jan. 12, 2016 CAD ($)	Aug. 18, 2015 USD ($) shares	Aug. 18, 2015 USD ($) shares	Jun. 30, 2015 USD ($)	Oct. 15, 2014 USD ($)	Jun. 27, 2014 USD ($)	Mar. 31, 2011 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 CAD ($) shares	Dec. 31, 2016 $ / shares shares	Jul. 28, 2016 USD ($)	Oct. 30, 2015 USD ($)
Unreimbursed patent fees																	$ 17,000
Due and payable investment banking services							$ 225,000
Arbitrator awarded amount					$ 146,082
Attorneys' fees and costs					$ 47,937
Percentage of annual bonus from base salary			4.50%
Accrued interest			$ 5,239
Cash compensation expense				$ 2,557,083
Stock options to purchase | shares																	4,344,944	3,996,167	3,996,167	1,307,749
Stock option exercisable term				10 years													6 years 3 months 19 days	5 years 3 months 22 days
Stock option exercise price per share | $ / shares				$ 1.45													$ 3.5414	$ 3.7634		$ 7.6515
Options exercisable shares of common stock | shares				1,772,055													4,344,994	3,996,167	3,996,167	1,307,749
Number of common stock shares issued	$ 198,550			$ 2,475,561														$ 734,500
Forgive accrued compensation and related accrued expenses				2,668,718
Research and development expenses																	$ 688,286	1,499,940
Accounts payable		$ 124,025
Principal cash obligations and commitments																	995,900
Employment Agreements [Member] | Tranche One [Member]
Cash bonuses												$ 15,000
Employment Agreements [Member] | Tranche Two [Member]
Cash bonuses												15,000
Employment Agreements [Member] | Tranche Three [Member]
Cash bonuses												30,000
Excess of financing cost												200,000
Recurring Cash Compensation Accrued Pursuant Amended Agreement [Member]
Cash compensation expense																	321,600
University of Alberta License Agreement [Member]
Unreimbursed patent fees																	$ 17,000
University of Illinois 2014 Exclusive License Agreement [Member]
License agreement effective date														Sep. 18, 2014
License fee														$ 25,000
Outstanding patent costs														$ 15,840
Percentage of royalty on net sale																	4.00%
Percentage of payment on sub licensee revenue																	12.50%
Minimum annual royalty payment amount																	$ 100,000
Royalty due date																	Feb. 28, 2019
Research and development expenses																	$ 100,000	100,000
Charge to operations with stock options																	100,000	100,000
University of Illinois 2014 Exclusive License Agreement [Member] | Research and Development Expenses [Member]
Minimum annual royalty payment amount																	250,000
Neuroscience and Mental Health Institute at University of Alberta [Member]
Research and development expenses																	0	0
Research grants award amount								$ 111,000
Additional cost budgeted under research grant								65,000
Funding cash installments								16,000
Payments to patent costs								15,000
Underwrite additional budgeted costs								$ 15,000
Accounts payable																		$ 16,207
Foreign conversion exchange rate								0.76	0.76
Duke University Clinical Trial Agreement [Member]
Amount payable																					$ 678,327	$ 678,327
Budgeted cost						$ 35,958
Jeff E. Margolis [Member]
Cash compensation expense				$ 560,876
Cash bonuses												60,000
Options exercisable shares of common stock | shares				388,687
Jeff E. Margolis [Member] | Employment Agreements [Member]
Cash bonuses												60,000
Excess of financing cost												100,000
Dr. Arnold S.Lippa [Member]
Cash compensation expense				$ 807,497
Cash bonuses												75,000
Options exercisable shares of common stock | shares				559,595
Dr. James S. Manuso [Member]
Cash compensation expense				$ 878,360
Options exercisable shares of common stock | shares				608,704
James E. Sapirstein [Member]
Cash compensation expense				$ 55,000
Cash bonuses												10,000
Options exercisable shares of common stock | shares				38,114
Kathryn MacFarlane [Member]
Cash compensation expense				$ 55,000
Cash bonuses												10,000
Options exercisable shares of common stock | shares				38,114
Robert N Weingarten [Member]
Cash compensation expense				$ 200,350
Cash bonuses												60,000
Options exercisable shares of common stock | shares				138,842
Minimum [Member] | Jeff E. Margolis [Member] | Employment Agreements [Member]
Cash bonuses												15,000
Maximum [Member] | University of Illinois 2014 Exclusive License Agreement [Member] | First Sale Of Product [Member]
Minimum annual royalty payment amount																	150,000
Maximum [Member] | University of Illinois 2014 Exclusive License Agreement [Member] | First Commercial Sale Of Product [Member]
Minimum annual royalty payment amount																	200,000
Additional [Member] | Jeff E. Margolis [Member] | Employment Agreements [Member]
Excess of financing cost												$ 250,000
Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member] | University of Illinois 2014 Exclusive License Agreement [Member]
Payment for sale of product																	350,000
Due Within Five Days After First New Drug Application Filing [Member] | University of Illinois 2014 Exclusive License Agreement [Member]
Payment for sale of product																	500,000
Due Within Twelve Months of First Commercial Sale Member [Member] | University of Illinois 2014 Exclusive License Agreement [Member]
Payment for sale of product																	1,000,000
Mr. Manuso [Member]
Percentage of annual bonus from base salary										50.00%
Cash compensation expense										$ 375,000
Stock options to purchase | shares										261,789	261,789
Health plan for employees expense										$ 1,200
Maximum health coverage amount per month										$ 1,000
Mr. Manuso [Member] | 2015 Stock and Stock Option Plan [Member]
Stock options to purchase | shares																		125,000	125,000
Dr. Manuso [Member]
Cash compensation expense				$ 878,360													310,950	$ 414,600
Stock options to purchase | shares				608,704
Dr. Arnold S.Lippa [Member]
Percentage of annual bonus from base salary											50.00%
Cash compensation expense											$ 300,000						339,600	339,600
Stock options to purchase | shares										30,769	30,769
Health plan for employees expense											$ 1,200
Maximum health coverage amount per month											1,000
President And Chief Executive Officer [Member]
Cash compensation expense				$ 94,758
Dr. Lippa [Member]
Cash compensation expense				$ 807,497
Stock options to purchase | shares				559,595
Mr Margolis [Member]
Cash compensation expense											$ 195,000
Stock options to purchase | shares										30,769	30,769
Health plan for employees expense											$ 1,200
Maximum health coverage amount per month											1,000
Mr Margolis [Member] | Recurring Cash Compensation Accrued Pursuant Amended Agreement [Member]
Cash compensation expense																		269,100
Mr Margolis [Member] | Minimum [Member]
Bonuses										$ 65,000	65,000
Mr Margolis [Member] | Maximum [Member]
Bonuses										$ 125,000	$ 125,000
Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten [Member]
Net proceeds from offering cost																	2,000,000
Robert N Weingarten [Member]
Forgive accrued compensation and related accrued expenses		$ 200,350
Robert N Weingarten [Member] | 2015 Plan [Member]
Stock option exercisable term		10 years
Stock option exercise price per share | $ / shares		$ 1.12
Stock option exercisable value		$ 200,404
Biovail [Member]
Reimbursement related expenses																$ 15,000,000
Payments for future potential															$ 15,150,000
Additional payments received upto															$ 15,000,000
DNA Healthlink, Inc [Member] | Richard Purcell [Member]
Cash fee													$ 12,500
Cash compensation expense																	37,500	$ 37,500
CAD [Member]
Unreimbursed patent fees																	23,000
CAD [Member] | University of Alberta License Agreement [Member]
Unreimbursed patent fees																	$ 23,000
CAD [Member] | Neuroscience and Mental Health Institute at University of Alberta [Member]
Research grants award amount									$ 146,000
Additional cost budgeted under research grant									85,000
Funding cash installments									21,000
Payments to patent costs									20,000
Underwrite additional budgeted costs									$ 20,000
Accounts payable																			$ 21,222
Foreign conversion exchange rate								1.00	1.00